Zu den gestationsbedingten Trophoblasterkrankungen zählen: Partialmole, Blasenmole, trophoblastäre Neoplasien. Kennzeichnend sind eine Fehldifferenzierung und/oder Proliferation des Trophoblastepithels.
, die in der angloamerikanischen Literatur als gestational trophoblastic disease (gestationsbedingte Trophoblasterkrankungen) bezeichnet werden, umfassen eine in Bezug auf ihre Genese und klinische Bedeutung heterogene Gruppe von Krankheitsbildern, die durch eine Fehldifferenzierung und/oder Proliferation des Trophoblastepithels gekennzeichnet ist. Mit einem klinisch sehr unterschiedlichen Erscheinungsbild handelt es sich sowohl um benigne als auch hochmaligne Erkrankungen.
In Abhängigkeit vom klinischen Bild und ihrer Morphologie werden in Anlehnung an die WHO-Klassifikation [[1]] eine Reihe Läsionen unterschieden (Tab. [1]).
Der Terminus gestationsbedingte Trophoblasterkrankung ist ein Überbegriff und beinhaltet die Partial- und Blasenmole sowie die gestationsbedingten trophoblastären Neoplasien (GTN).
Literatur
1 Scully R E, Bonfiglio T A, Kurman R J, Silverberg S G, Wilkinson E J. WHO - Histological Typing of Female Genital Tract Tumours. Berlin, Heidelberg, New York, London, Paris, Tokyo, Hong Kong, Barcelona, Budapest; Springer 1994
2
Ngan H YS, Odicino F, Maisonneuve P, Beller U, Benedt J L, Heintz A PM, Pecorelli S, Siderei M, Creasman W T.
Gestational trophoblastic disease.
J Epidemiol Biostat.
2001;
6
177-184
4
Kim S J, Bae S N, Kim J H, Kim C J, Han K T, Chung J K, Lee J M.
Epidemiology and time trends of gestational trophoblastic disease in Korea.
Int J Gynaecol Obstet.
1998;
60 (Suppl 1)
S33-38
5
Kohorn E I.
The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assesssment.
Int J Gynecol Cancer.
2001;
11
73-77
6
Horn L C, Rosenkranz M, Bilek K.
Wertigkeit der Plazentahistologie für die Erkennung genetisch bedingter Aborte.
Z Geburtsh Perinatol.
1991;
195
47-53
7
Horn L C, Emmrich P, Bilek K, Bruder E.
Der frühe plazentare Trophoblast: II. Tumorförmige Störungen der trophoblastären Entwicklung.
Zentralbl Gynäkol.
1996;
118
591-597
8
Seckl M J, Fisher R A, Salerno G, Rees H, Paradinas F J, Foskett M, Newlands E S.
Choriocarcinoma and partial hydatidiform moles.
Lancet.
2000;
356
1443-1444
9
Bilek K, Horn L C, Abu Hmeidan F, Pretzsch G.
Gestationsbedingte Trophoblasterkrankungen - Ergebnisse der Jahre 1976 - 1992.
Geburtsh Frauenheilk.
1994;
54
519-523
13
Lan Z, Hongzaho S, Xiuyu Y, Yang X.
Pregnancy outcomes of patients who conceived within 1 year after chemotherapy for gestational trophoblastic tumor: A clinical report of 22 patients.
Gynecol Oncol.
2001;
83
146-148
14
Lorigan P C, Sharma S, Bright N, Coleman R E, Hancock B W.
Characteristics of women with recurrent molar pregnancies.
Gynecol Oncol.
2000;
78
288-292
15
Kim J H, Park D C, Bae S N, Namkoong S E, Kim S J.
Subsequent reproductive experience after treatment for gestational trophoblastic disease.
Gynecol Oncol.
1998;
71
108-112
16
Garner E IO, Lipson E, Bernstein M R, Goldstein D P, Berkowitz R S.
Subsequent pregnancy experience in patients with molar pregnancy and gestational trophoblastic tumor.
J Reprod Med.
2002;
47
380-386
17
Shih I M, Kurman R J.
Epitheloid trophoblastic tumor - a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma.
Am J Surg Pathol.
1998;
22
1393-1403
27
Shih I M, Seidman J D, Kurman R J.
Placental site nodule and characterisation of distinctive types of intermediate trophoblast.
Hum Pathol.
1999;
30
687-694
29
Hui P, Parkash V, Perkins A S, Carcangiu M L.
Pathogenesis of placental site trophoblastic tumor may require the presence of a paternally derived X chromosome.
Lab Invest.
2000;
80
965-972
30
Newlands E S, Mulholland P J, Holden L, Seckl M J, Rustin G J.
Etoposide and cisplatin/etoposide, methotrexate and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophpsphamide and vicncristine chemotherapy and patients representing with metastatic placental site trophoblastic tumors.
J Clin Oncol.
2000;
18
854-859
31
Papadopoulos A J, Foskett M, Seckl M J, McNeish I, Paradinas F J, Rees H, Newlands E S.
Twenty-five year's clinical experience with placental site trophoblastic tumors.
J Reprod Med.
2002;
47
460-464
32
Denny L A, Dehaeck K, Nevin J, Soeters R, van Wuk A L, Megevand E, Block B.
Placental site trophoblastic tumor: Three case reports and literature review.
Gynecol Oncol.
1995;
59
300-303
34
Schmidt D, Baijka M, Köchli O, Robbiani M, Stallmach T.
Plazentabett-Tumor: Morphologie, Differentialdiagnose und Prognose.
Pathologe.
1995;
16
315-320
35
Hammond C B, Borchert L G, Tyrey L. et al .
Treatment of metastatic trophoblastic disease: Good and poor prognosis.
Am J Obstet Gynecol.
1973;
115
4-8
37
Curry S L, Blessing J A, DiSaia P J, Soper J T, Twiggs L B.
A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in “poor prognosis” metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study.
Obstet Gynecol.
1989;
73
357-362
38
Newlands E S, Bagshawe K D, Begent R H, Rustin G J, Holden L, Dent J.
Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979 - 1984).
Br J Obstet Gynaecol.
1986;
93
63-69
41
Schink J C, Singh D K, Rademaker A W, Miller D S, Lurain J R.
Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease.
Obstet Gynecol.
1992;
80
817-820
42
Soper J T, Evans A C, Conaway M R, Clarke-Pearson D L, Berchuck A, Hammond C B.
Evaluation of prognostic factors and staging in gestational trophoblastic tumor.
Obstet Gynecol.
1994;
84
969-973
43
Surwit E A, Childers J M.
High-risk metastatic gestational trophoblastic disease. A new dose-intensive, multiagent chemotherapeutic regimen.
J Reprod Med.
1991;
36
45-48
44
Bagshawe K D, Dent J, Newlands E S, Begent R H, Rustin G J.
The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumors.
Brit J Obstet Gynaecol.
1989;
96
795-802
45
McNeish I A, Strickland S, Holden L, Rustin G J, Foskett M, Seckl M J, Newlands E S.
Low-risk peristent gestational trophoblastic disaese: Outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.
J Clin Oncol.
2002;
20
838-844
46
Roberts J P, Lurain J R.
Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy.
Am J Obstet Gynecol.
1996;
174
1917-1923
49
Dobson L S, Lorigan P C, Coleman R E, Hancock B W.
Persistent gestational trophoblastic disease: Results of MEA (methotrexate, etoposide and dactinomycine) as first-line chemotherapy in hight risk disease and EA (etoposide and dactinomycine) as second-line therapy for low risk disease.
Brit J Cancer.
2000;
82
1547-1552
50
Bower M, Paradinas F J, Fisher R A, Nicholson S K, Rustin G J, Begent R H, Bagshawe K D, Newlands E S.
Placental site trophoblastic tumor: Molecular analysis and clinical experience.
Clin Cancer Res.
1996;
2
897-902
